Twelve of the 15 analysts surveyed by S&P Global (NYSE: SPGI) in April rated the pharmaceutical stock as a "buy" or "strong ...

The Class II recall covers 3 dosages of clonidine transdermal patches made by Actavis Laboratories, with no adverse health ...

The Federal Circuit reversed a ruling that had wiped out Teva Pharmaceuticals International GmbH’s $177 million Ajovy patent ...

Viatris and Teva Pharmaceutical Industries recently launched separate recalls in the U.S. related to dissolution problems for ...

The model fair value for Teva Pharmaceutical Industries has shifted slightly, moving from US$37.82 to US$38.18 per share.

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival ...

TCW funds, an investment management company, released its “TCW Relative Value Mid Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities finished the year ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 13 Cheapest Strong Buy Stocks to Buy Right Now. On March 30, ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) rallied after it reported earnings on Nov. 5. The stock is now higher by a whopping 45% in roughly a month. The company reported strong results, ...

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground(TM) Schizophrenia Community is a centralized destination ...

A U.S. appeals court on Thursday revived a patent lawsuit that Teva Pharmaceutical brought ​against Eli Lilly over the ...